Oruka Therapeutics, Inc.
ORKA
$29.57
$1.746.23%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 17.85% | -15.87% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 19.97% | 13.33% | |||
| Operating Income | -19.97% | -13.33% | |||
| Income Before Tax | -23.21% | -17.02% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -23.21% | -17.02% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -23.21% | -17.02% | |||
| EBIT | -19.97% | -13.33% | |||
| EBITDA | -19.98% | -13.32% | |||
| EPS Basic | -18.84% | -16.11% | |||
| Normalized Basic EPS | -17.68% | -15.88% | |||
| EPS Diluted | -18.84% | -16.11% | |||
| Normalized Diluted EPS | -17.68% | -15.88% | |||
| Average Basic Shares Outstanding | 4.68% | 1.00% | |||
| Average Diluted Shares Outstanding | 4.68% | 1.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||